KRAS and non-small cell lung carcinoma: Furthermore, given that KRAS is known to play a major role in altering the metabolic landscape of NSCLC, it is important to elucidate whether Shp2 can also cause metabolic alterations in this setting and whether these alterations are impacted by the presence of Shp2 inhibition [39,40].